Yu Xu1, Cuiming Cao2, Xiuchun Gong3, LiJun Rong4. 1. Department of Haematology, People's Hospital of Linyi Shandong, China. 2. Department of Medical Laboratory Diagnosis Center, Jinan Central Hospital Jinan, Shandong, China. 3. Department of Clinical Laboratory, People's Hospital of Linyi Shandong, China. 4. Department of Clinical Laboratory, People's Hospital of LinYi Shandong, China.
Abstract
BACKGROUND AND AIMS: Acute myeloid leukemia (AML) is a fatal hematological malignancy which is resistant to a variety of chemotherapy drugs. Phospho-ERK5 (p-ERK5) plays a novel role in chemoresistance in some cancer cells and this pathway is a central mediator of cell survival and apoptotic regulation. The aim of this study was to investigate the effect of a specific ERK5 small interference RNA (siRNA) on proliferation and the sensitivity of HL-60 acute myeloid leukemia (AML) cells to the chemotherapeutic drug cytarabine. METHODS: The cells were transfected with siRNAs using Lipofectamine™ 2000 transfection reagent. Relative ERK5 mRNA and protein levels were measured by quantitative real-time PCR, immunocytochemical assay, and Western blotting, respectively. The cytotoxic effects of cytarabine and ERK5 siRNA, alone and in combination, on leukemic cells were determined using colony formation and MTT assay. Apoptosis was assessed by ELISA cell death assay. RESULTS: ERK5 siRNA markedly reduced both mRNA and protein expression levels leading to distinct inhibition of cell proliferation and increased spontaneous apoptosis. Surprisingly, ERK5 siRNA synergistically increased the cell toxic effects of cytarabine. CONCLUSIONS: Our study suggests that down-regulation of ERK5 by siRNA can trigger apoptosis and overcome drug resistance of leukemia cells. Therefore, ERK5 siRNA may be an effective adjuvant in AML chemotherapy.
BACKGROUND AND AIMS: Acute myeloid leukemia (AML) is a fatal hematological malignancy which is resistant to a variety of chemotherapy drugs. Phospho-ERK5 (p-ERK5) plays a novel role in chemoresistance in some cancer cells and this pathway is a central mediator of cell survival and apoptotic regulation. The aim of this study was to investigate the effect of a specific ERK5 small interference RNA (siRNA) on proliferation and the sensitivity of HL-60 acute myeloid leukemia (AML) cells to the chemotherapeutic drug cytarabine. METHODS: The cells were transfected with siRNAs using Lipofectamine™ 2000 transfection reagent. Relative ERK5 mRNA and protein levels were measured by quantitative real-time PCR, immunocytochemical assay, and Western blotting, respectively. The cytotoxic effects of cytarabine and ERK5 siRNA, alone and in combination, on leukemic cells were determined using colony formation and MTT assay. Apoptosis was assessed by ELISA cell death assay. RESULTS:ERK5 siRNA markedly reduced both mRNA and protein expression levels leading to distinct inhibition of cell proliferation and increased spontaneous apoptosis. Surprisingly, ERK5 siRNA synergistically increased the cell toxic effects of cytarabine. CONCLUSIONS: Our study suggests that down-regulation of ERK5 by siRNA can trigger apoptosis and overcome drug resistance of leukemia cells. Therefore, ERK5 siRNA may be an effective adjuvant in AML chemotherapy.
Authors: Lisa-Marie Sturla; Christopher W Cowan; Lillian Guenther; Robert C Castellino; John Y H Kim; Scott L Pomeroy Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: S R C McCracken; A Ramsay; R Heer; M E Mathers; B L Jenkins; J Edwards; C N Robson; R Marquez; P Cohen; H Y Leung Journal: Oncogene Date: 2007-12-10 Impact factor: 9.867
Authors: Xuening Wang; Stella Pesakhov; Jonathan S Harrison; Michael Danilenko; George P Studzinski Journal: J Cell Physiol Date: 2014-07 Impact factor: 6.384
Authors: Christopher B Weldon; Ali B Scandurro; Kevin W Rolfe; John L Clayton; Steven Elliott; Nancy N Butler; Lilia I Melnik; Jawed Alam; John A McLachlan; Bernard M Jaffe; Barbara S Beckman; Matthew E Burow Journal: Surgery Date: 2002-08 Impact factor: 3.982
Authors: Patricia Macanas-Pirard; Richard Broekhuizen; Alfonso González; Claudia Oyanadel; Daniel Ernst; Patricia García; Viviana P Montecinos; Felipe Court; Mauricio Ocqueteau; Pablo Ramirez; Bruno Nervi Journal: Oncotarget Date: 2017-04-04